ArriVent Biopharma (Series B)
Funding Details
- Awarder
- Inbox
- Date Award
- March 27, 2023
- Vertical
- Biopharmaceuticals
- Funding URL
- View Funding Page
- Funding Amount:
- $155,000,000
Company Info
- Founders
- Bing Yao
- Company Description
- ArriVent develops pharmaceutical products to cure presently untreatable cancer.
- Market
- Oncology
- Location
- Newton Square, PA, USA
- Coinvestors
- AIHC Capital, Boyu Capital, Catalio Capital Management, General Catalyst Partners, HBM Healthcare Investments, Infinitum Asset Management, Lilly Asia Ventures, Octagon Capital, OrbiMed Advisors, Sequoia China, Shanghai Healthcare Capital, Sirona Capital, Sofinnova Ventures, Terra Magnum Capital Partners, Unicorn Capital Partners Limited